AlGhamdi Khalid M, Kumar Ashok, Alfayez Musaad, Mahmood Amer
Vitiligo Research Chair, Department of Dermatology, College of Medicine, King Saud University, P.O. Box 240997, Riyadh, 11322, Saudi Arabia.
Department of Dermatology, College of Medicine, King Saud University, Derma-82, P.O. Box 7805, Riyadh, 11472, Saudi Arabia.
Lasers Med Sci. 2025 Jul 22;40(1):323. doi: 10.1007/s10103-025-04564-y.
Mesenchymal stem cells (MSCs) are widely studied for their regenerative capacities in bone tissue repair. Low-level laser therapy (LLLT) has emerged as a promising method to stimulate stem cell proliferation, viability, and differentiation. In this study, we focus on how low-level blue-laser treatment (457 nm) affects human embryonic stem cell-derived mesenchymal stem cells (hESC-MSCs) at various energy densities, highlighting its potential to enhance osteogenic differentiation for clinical applications in treating osteoporosis. To determine how low-level blue-laser treatment at various energy densities (0.5-5.0 J/cm²) influences the proliferation, viability, migration, and osteogenic differentiation of hESC-MSCs. hESC-MSCs were cultured to near confluence, then irradiated at doses ranging from 0.5 to 5.0 J/cm². Cell proliferation, viability, and migration were assessed at 72 h. Flow cytometry evaluated CD146 expression, and Alkaline phosphate (ALP) activity was measured. Osteogenic gene expression (Runx2, ALP, BMP2, BMP4, and osteonectin) and in vitro mineralization were also examined. Blue-laser treatment at 0.5-3.5 J/cm² significantly increased cell proliferation (p < 0.01) and viability (p < 0.05), while migration was enhanced at 0.5-2.5 J/cm² (p < 0.001). CD146 expression rose at 0.5, 1.0, and 2.0 J/cm², with a 1.9-fold increase in ALP activity at 2.0 J/cm². Osteogenic markers and mineralization were likewise upregulated at 2.0 J/cm², indicating enhanced osteoblast differentiation. These findings indicate that LLLT combined with a blue laser results in changes in various biological processes at the cellular and genetic levels in hESC-MSCs, indicating that these cells are sensitive to blue laser treatment. Thus, these results demonstrate that hMSCs are responsive to blue-laser treatment, which may be used in the clinic to treat osteoporosis.
间充质干细胞（MSCs）因其在骨组织修复中的再生能力而受到广泛研究。低强度激光疗法（LLLT）已成为一种有前景的刺激干细胞增殖、活力和分化的方法。在本研究中，我们聚焦于低强度蓝光治疗（457nm）在不同能量密度下如何影响人胚胎干细胞来源的间充质干细胞（hESC-MSCs），突出其在增强成骨分化方面的潜力，以用于治疗骨质疏松症的临床应用。为了确定不同能量密度（0.5 - 5.0J/cm²）的低强度蓝光治疗如何影响hESC-MSCs的增殖、活力、迁移和成骨分化。将hESC-MSCs培养至接近汇合状态，然后以0.5至5.0J/cm²的剂量进行照射。在72小时时评估细胞增殖、活力和迁移。通过流式细胞术评估CD146表达，并测量碱性磷酸酶（ALP）活性。还检测了成骨基因表达（Runx2、ALP、BMP2、BMP4和骨连接蛋白）和体外矿化情况。0.5 - 3.5J/cm²的蓝光治疗显著增加细胞增殖（p < 0.01）和活力（p < 0.05），而在0.5 - 2.5J/cm²时迁移增强（p < 0.001）。在0.5、1.0和2.0J/cm²时CD146表达升高，在2.0J/cm²时ALP活性增加1.9倍。在2.0J/cm²时成骨标志物和矿化同样上调，表明成骨细胞分化增强。这些发现表明，LLLT联合蓝光会导致hESC-MSCs在细胞和基因水平上的各种生物学过程发生变化，表明这些细胞对蓝光治疗敏感。因此，这些结果证明hMSCs对蓝光治疗有反应，这可能在临床上用于治疗骨质疏松症。
